高级检索
当前位置: 首页 > 详情页

Inhibition of interleukin-6 function attenuates the central sensitization and pain behavior induced by osteoarthritis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Anesthesiology, West China Second Hospital, Sichuan University, Chengdu, Sichuan, China [2]Key Laboratory of Birth Defects and Related Disease of Women and Children(Sichuan University), Ministry of Education, Chengdu, China [3]Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Sichuan University, Chengdu, Sichuan, China [4]Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China [5]Department of Anesthesiology and Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
出处:
ISSN:

关键词: Tocilizumab IL-6 Microglia Astrocyte Osteoarthritis

摘要:
Chronic pain is the most prominent and disabling symptom in the patients with osteoarthritis (OA), and the underlying mechanism largely remains unclear. Interleukin-6 (IL-6), a proinflammatory cytokine, is critically involved in the development and maintenance of central sensitization in several rodent models of chronic pain. The present study aims to elucidate the IL-6 mediated neurological adaptation in dorsal horn in the rat with monosodium iodoacetate (MIA) -induced OA. Significant upregulation of IL-6 expression was detected in the dorsal horn in the modeled rats. Blockade of IL-6 function by tocilizumab markedly suppressed the activation of astrocytes and microglia in the ipsilateral dorsal horn, reduced c-Fos immunoreactivity in dorsal horn neurons, and attenuated the upregulation of glutamate receptor subunits GluR1 and NR2B in dorsal horn in the rats with MIA-induced OA. It was further reported that administration of tocilizumab significantly improved the performance in weight-bearing test and mitigated the mechanical allodynia in the modeled rats. These data illustrated spinal IL-6 mediated mechanism underlying the chronic pain, and proposed the potential therapeutic effect of tocilizumab on the chronic pain in the setting of OA.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 药学
最新[2023]版:
大类 | 3 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2017]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Anesthesiology, West China Second Hospital, Sichuan University, Chengdu, Sichuan, China [2]Key Laboratory of Birth Defects and Related Disease of Women and Children(Sichuan University), Ministry of Education, Chengdu, China
通讯作者:
通讯机构: [*1]No. 20, Section 3, South of Renmin Road, Chengdu 610041, Sichuan, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)